drugset / Trial / NCT00950586

Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702

NCT00950586

Phase 1 Completed 48 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men and women of no child beading potential to investigate repeated doses of the study medicine. The study will investigate the following questions, do repeated doses of the study medicine have any important side effects when taken by mouth? How much of the study medicine gets into the bloodstream, and how quickly does the body get rid of it? Does the study medicine affect memory, attention and problem-solving skills? What are the effects when the study medicine and dextromethorphan are taken together.

Timeline

Start
2009-08-24
Primary completion
2009-12-24
Completion
2009-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown 30 mg Oral
Subject GSK1043702 Unknown Oral

Indications